[Effect of glycine-steatamide or glutamic acid palmitamide on oral dyskinesia, obtained by a single administration of haloperidol combined with GABA-linoleamide in rats].
Vamvakidès
A
A
D000818:Animals; D004338:Drug Combinations; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D005971:Glutamates / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006220:Haloperidol; D010169:Palmitic Acids / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013229:Stearic Acids / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives
D004338:Drug Combinations; D005971:Glutamates; D010169:Palmitic Acids; D011619:Psychotropic Drugs; D013229:Stearic Acids; C059900:glutamic acid palmitamide; D005680:gamma-Aminobutyric Acid; C059899:glycine stearamide; C036611:gabalid; D006220:Haloperidol; D005998:Glycine
Effet du stéatamide de glycine ou du palmitamide de l'acide glutamique sur les dyskinésies orales, obtenues par administration unique d'halopéridol associé au GABA-linoléamide chez le Rat.